Recombinant Virus Vaccine-Induced SIV-specific CD8 + Cytotoxic T Lymphocytes
1991; American Association for the Advancement of Science; Volume: 252; Issue: 5004 Linguagem: Inglês
10.1126/science.1708168
ISSN1095-9203
AutoresLing Shen, Zheng W. Chen, Michael D. Miller, Virginia Stallard, Gail P. Mazzara, Dennis Panicali, Norman L. Letvin,
Tópico(s)T-cell and B-cell Immunology
ResumoEvidence indicates that cytotoxic T lymphocytes (CTLs) may be important in containing the spread of the human immunodeficiency virus (HIV) in the infected host. Although the use of recombinant viruses has been proposed as an approach to elicit protective immunity against HIV, the ability of recombinant viral constructs to elicit CD8+ CTL responses in higher primates has never been demonstrated. A live recombinant virus, vaccinia-simian immunodeficiency virus of macaques (SIVmac), was used to determine whether such a genetically restricted, T lymphocyte-mediated antiviral response could be generated in a primate. Vaccinia-SIVmac vaccination elicited an SIVmac Gag-specific, CD8+ CTL response in rhesus monkeys. These CTLs recognized a peptide fragment that spans residues 171 to 195 of the Gag protein. The rhesus monkey major histocompatibility complex (MHC) class I gene product restricting this CTL response was defined. Both the vaccinated and SIVmac-infected monkeys that shared this MHC class I gene product developed CTLs with the same Gag epitope specificity. These findings support the use of recombinant virus vaccines for the prevention of HIV infections in humans.
Referência(s)